Data extraction
Our primary outcome was mortality, and second ary outcomes included patientreported or other clinically important outcomes. We calculated the relative risk (RR), unless count data were not reported, in which case we extracted the authors' RR. We used adjusted RRs whenever they were reported. 5 When RRs could not be calculated, we assumed that the reported odds ratios (ORs) approximated the RR for low eventrate outcomes.
For continuous outcomes, we extracted mean betweengroup differences and their standard deviations. We created rules for calculating missing outcomes using various statistical meas ures that were reported (Table 1) .
Prespecified causes of heterogeneity
We used the I 2 statistic to measure the extent of heterogeneity between studies, where I 2 values of 25%, 50% and 75% indicated low, medium and high heterogeneity, respectively. 6 In addi tion, we constructed a priori hypotheses to potentially explain betweenstudy heterogeneity, based on differences in types of outcomes, meth odologic quality, types of care provided, poten tial for detection bias (due to differential follow up or use of better diagnostic tools), potential for exclusion bias (if patients were excluded after enrolment because of characteristics related to outcome), potential for selection bias (due to imbalance of baseline characteristics), medical specialty and treatments provided.
In particular, we proposed 6 subgroups to explain observed heterogeneity due to treatment effect: 1. when the randomized experimental interven tion given to "insiders" was effective (i.e., the outcome was statistically significantly su perior to the comparator), and "outsiders" received that same intervention or comparator 2. when the randomized experimental interven tion was effective, and "outsiders" received that same effective intervention only (without the comparator that was provided within the RCT) 3. when the randomized experimental interven tion was effective, and "outsiders" received the less effective comparator intervention only (without the experimental intervention provided within the RCT) 4. when the randomized experimental interven tion was effective, and "outsiders" received a different intervention (this subgroup acted as a positive control for the current analysis, since we anticipated better outcomes in the RCT group) 5. when the randomized experimental and com parator interventions generated equivalent outcomes, with no further subdivision of this group (because any differences in outcomes between those treated inside and outside the RCT could be attributed to a trial effect) 6. when insufficient information was provided about the effectiveness of the treatment in the trial and/or insufficient details were pro vided about the interventions received by "outsiders"
Data synthesis and analysis
Statistical calculations were performed with SPSS (version 20). 7 Forest plots and funnel plots were created using Review Manager (version 5.1). 8 When event counts were available, we used the Mantel-Haenszel method to estimate overall RR. 9 If a study had a zero event rate in one group, we added a 0.5 correction to all cells. If only estimates of effect size and standard errors were provided, we used the generic inversevariance metaanalysis function of Review Manager 5.1. We used the random effects model to summarize outcomes. 9 We first separated the studies into 2 groups according to whether randomization was applied in determining whether potential participants would be "insiders" or "outsiders." Next, we separated studies by type of outcome: continuous or dichotomous, with the latter being further sub divided as nonmortality or mortality.
We created a funnel plot and conducted a sensitivity analysis to determine the stability of our conclusions.
Results

Summary of evidence
Following elimination of duplicate records and exclusions on the basis of initial screening and fulltext review, 147 articles met our eligibility criteria and provided sufficient information to be included in our analysis ( Figure 1 ). Details for the 576 articles excluded after fulltext review, including reasons for exclusion, are available upon request. The eligibility of the remaining 74 articles was uncertain, and they were not included in the analysis.
For fulltext screening, the calculated average of the weighted kappa for eligibility was 0.68. There was 83% raw agreement between review ers in the dataextraction phase for outcomes.
In 5 of the 147 eligible studies, patients were randomly assigned to become "insiders" and "outsiders." 38, 41, 86, 87, 141 In the remaining 142 studies, patients became part of the "outsiders" group for a variety of reasons. Table 2 presents the details about each included study.
We analyzed a total of 48 continuous out comes and 99 dichotomous outcomes; of the dichotomous outcomes, 74 were nonmortality outcomes, 4 were recurring outcomes (such as relapse rates), and 21 were mortality outcomes.
Risk of bias
Sources of risk of bias are detailed by individual study in Appendix 1 (available at www.cmaj.ca /lookup /suppl/doi:10.1503/cmaj.131693//DC1). In terms of detection bias, about twothirds of the studies (n = 100) employed identical follow up strategies for "insiders" and "outsiders." In terms of exclusion bias affecting "insiders," 67 studies had no exclusions, 1 study employed a deliberate but appropriate exclusion, and 74 studies inappropriately excluded "insiders" unequally between treatment groups; for the remaining 5 studies, the details were unclear. Forest plots based on subgroups created for each of these sources of bias did not change the results described below.
Records identi ed through database searching n = 42 493
Records screened n = 21 045
Full-text articles assessed for eligibility n = 797
Included in quantitative synthesis (meta-analysis) n = 147
Excluded n = 20 248
Excluded n = 650
• With reasons n = 576
• Eligibility uncertain n = 74
Excluded (duplicates) n = 21 448 
Replication of earlier studies
As a method of calibrating our search strategies and statistical methods, we carried out analyses of our dataset that were restricted to "insiders" and "outsiders" receiving identical treatments. These restricted analyses replicated the results of previous studies by Vist and colleagues 4 and Gross and associates.
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Outcomes for studies with participants not randomized as "insiders" or "outsiders" Our initial pooled analyses revealed a high degree of betweenstudy heterogeneity (p < 0.001, I 2 = 84% for studies with dichotomous mortality outcomes; p < 0.001, I 2 = 70% for studies with dichotomous nonmortality out comes; p < 0.001, I 2 = 88% for studies with con tinuous outcomes). In total, mortality was deter mined for 53 714 "insiders" and 25 817 "outsiders" (see Table 3 and Appendix 2, avail able at www.cmaj.ca/lookup/suppl/doi:10.1503 /cmaj .131693//DC1). Dichotomous nonmortality outcomes were reported for 30 253 "insiders" and 30 000 "outsiders" (see Table 4 and Appendix 3, available at www.cmaj.ca/lookup/suppl /doi:10.1503 /cmaj.131693//DC1). We present the results of our nonrandomized continuous outcomes and randomized comparisons according to treat ment effects, by presenting the subgrouping that left the least amount of remaining heterogeneity. All other forest plots are available upon request.
Results for clinically relevant subgroups
The results for continuous outcomes are sum marized by subgroup in Table 5 (see also Appendix 4, available at www.cmaj.ca/lookup /suppl /doi:10.1503/cmaj.131693//DC1).
There were 7 studies in which the randomized experimental intervention given to "insiders" Note: ASA = acetylsalicylic acid, CASS = Coronary Artery Surgery Study, chemo = chemotherapy, ENT = ear, nose and throat, Family = family medicine, ID = infectious diseases, "insider" = patient receiving treatment within a randomized controlled trial, IVF = in vitro fertilization, Ob/gyn = obstetrics and gynecology, "outsider" = patient receiving treatment via routine clinical care outside the randomized controlled trial.
(n = 6626) was effective, and "outsiders" (n = 2293) received that same intervention or the comparator. The heterogeneity was low to mod erate (p = 0.2, I 2 = 37%), and the pooled result indicated neither significant harm nor significant benefit attributable to being an "insider" or an "outsider" (standardized mean difference 0.04, 95% confidence interval [CI] -0.04 to 0.13).
There were 3 studies in which the randomized experimental intervention (given to 1391 "insid ers") was effective, and the 5072 "outsiders" received only that same effective intervention. In this subgroup, there was a high degree of hetero geneity (p < 0.001, I 2 = 95%). There were 4 studies in which the randomized experimental intervention was effective, and Note: CI = confidence interval, NA = not applicable, RCT = randomized controlled trial, RR = relative risk. Note: CI = confidence interval, NA = not applicable, RCT = randomized controlled trial, RR = relative risk.
"outsiders" received only the less effective com parator. In these studies, the 5794 "insiders" (those assigned to receive the active intervention or comparator) experienced a positive effect of the intervention, but the 9035 "outsiders" were offered only the ineffective comparator. In this subgroup, there was also a high degree of hetero geneity (p = 0.01, I 2 = 74%). There were 9 studies in which the randomized experimental intervention had a positive effect inside the RCT, but "outsiders" received a com pletely different intervention or comparator. For these studies, results could be pooled for the 649 "insiders" and 188 "outsiders" (standardized mean difference -0.36, 95% CI -0.61 to -0.12, p = 0.08, I 2 = 43%). In this subgroup, "insiders" fared statis tically significantly better than "outsiders."
The largest subgroup consisted of 23 studies in which the randomized experimental and compara tor interventions generated equivalent outcomes. In this subgroup, the 5 940 "insiders" and 11 927 "outsiders" were given both treatments, only the control or only the experimental treatment, or completely different interventions. Heterogeneity among these studies was low to moderate (p = 0.10, I 2 = 29%). The pooled result revealed neither net harm nor net benefit for "insiders" compared with "outsiders" (standardized mean difference -0.03, 95% CI -0.1 to 0.04).
For the final subgroup of 2 studies, it was unclear whether there was a treatment effect or which interventions the "outsiders" received. We requested additional information from the study authors, but as of the date of publication, were still awaiting this clarification.
Outcomes for studies with participants randomized as "insiders" or "outsiders" In 5 studies, potential participants were randomly assigned to become "insiders" or "outsiders." One of these studies used a continuous outcome, with no reported difference between the 180 "insiders" and 97 "outsiders" (95% CI -0.22 to 0.27). The remaining 4 studies reported dichot omous nonmortality outcomes, with a moderate degree of heterogeneity (p = 0.06, I 2 = 60%). Their overall pooled effect indicated neither harm nor benefit when patients were treated inside or outside a trial (RR 0.94, 95% CI 0.56 to 1.57).
Additional analyses
Our investigation into publication bias showed a lack of smaller studies (both positive and nega tive) in our study. Because the included studies were symmetric around the pooled estimate, we are confident that our estimates are valid.
Our sensitivity analysis confirmed the robust nature of our imputations. Removing the studies with imputed outcomes had no significant effect on our results. Similarly, the results were not affected by clinical specialty.
Interpretation
Our study has confirmed the earlier findings of Vist and colleagues 4 and Gross and associates, 157 who reported that when trial participants ("insid Trial treatment effective, neither treatment nor comparator given to "outsiders" ers") and nonparticipants ("outsiders") receive the same treatments, they experience similar out comes. As such, there is neither a "trial advan tage" nor a "guinea pig disadvantage" of partici pating in an RCT. Furthermore, we have shown that even when "insiders" and "outsiders" are offered different interventions, there is no dis advantage to trial participation. Our findings do not support the theory of "inclusion benefits," "protocol effects" or "care effects" proposed by other authors. 3, 158 We found no differences in outcomes that could be attrib uted to health care workers providing additional care to "insiders," the setting in which "insiders" were treated or the closer followup and atten tion that "insiders" receive. Had there been bet ter care because physicians were following strict study protocol, a difference would have been detected between the groups for whom treat ments were identical and would have been amplified within the subgroup of studies in which detection bias and expertise bias were most probable.
As expected, our subanalysis of "insiders" and "outsiders" who received the same treatments con firmed the results of the Vist and Gross reviews. 4, 157 However, we suggest that their insistence on identi cal interventions for patients inside and outside of an RCT answered only a narrow, explanatory ques tion. For our review, we posed a more pragmatic question: Will patients fare better being treated within a trial (as "insiders") or in routine clin ical care outside it (as "outsiders"), regardless of the treatment received? In other words, will they be "sacrificial guinea pigs," or, conversely, will they enjoy an "inclusion benefit"? Or will they fare the same inside the RCT or outside it? Our pragmatic study supports the last of these options, that patients will, in general, fare just as well regardless of whether they are "insiders" or "outsiders."
Stiller 159 reported a beneficial effect on mortal ity for "insiders." However, that conclusion was based on simply counting the number of studies in which "insiders" had lower mortality than "outsid ers," ignoring the size of each study. As such, smaller studies (which are more prone to type II error) were weighted the same as much larger studies. Our randomeffects metaanalysis took into account the size and weight of each study, and we found no such benefit from trial participation.
Limitations
Although 68% of the studies included here employed identical followup protocols for both "insiders" and "outsiders," some studies did not explicitly state whether "outsiders" included all eligible patients or only those for whom data could be obtained. If "outsiders" are more likely to become lost to followup, in part because they have died or suffered other adverse events, true trial advantages might be missed.
Conclusion
We found no evidence to support either clinic ally important harm or clinically important bene fit when patients' illnesses were managed inside or outside an RCT. These results can inform dis cussions between clinicians and the patients to whom they are offering entry into peer reviewed, ethically conducted RCTs. These results are also relevant to the policies, proce dures and actions of institutions, ethics commit tees and granting agencies that permit and sup port the execution of RCTs.
Our findings and conclusions are only as good as the publication base of relevant RCTs, and we look forward to the day when the propos als of Vickers 160 and Altman and Cates 161 are fully realized, with all trials registered and reported and with raw trial data made readily available. When that day arrives, our study should be repeated to determine the validity of the conclusions reached here. 
